ATE314396T1 - G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung - Google Patents

G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung

Info

Publication number
ATE314396T1
ATE314396T1 AT99918932T AT99918932T ATE314396T1 AT E314396 T1 ATE314396 T1 AT E314396T1 AT 99918932 T AT99918932 T AT 99918932T AT 99918932 T AT99918932 T AT 99918932T AT E314396 T1 ATE314396 T1 AT E314396T1
Authority
AT
Austria
Prior art keywords
screening
csf receptor
receptor agonist
agonist antibodies
receptor
Prior art date
Application number
AT99918932T
Other languages
English (en)
Inventor
Baofu Ni
Bill N C Sun
Cecily R Y Sun
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Application granted granted Critical
Publication of ATE314396T1 publication Critical patent/ATE314396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
AT99918932T 1998-04-30 1999-04-30 G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung ATE314396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8357598P 1998-04-30 1998-04-30
PCT/US1999/009466 WO1999055735A1 (en) 1998-04-30 1999-04-30 G-csf receptor agonist antibodies and screening method therefor

Publications (1)

Publication Number Publication Date
ATE314396T1 true ATE314396T1 (de) 2006-01-15

Family

ID=22179233

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99918932T ATE314396T1 (de) 1998-04-30 1999-04-30 G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung

Country Status (12)

Country Link
EP (1) EP1073683B1 (de)
JP (1) JP3979008B2 (de)
KR (1) KR100479790B1 (de)
CN (2) CN101070344A (de)
AT (1) ATE314396T1 (de)
AU (2) AU764653B2 (de)
BR (1) BR9910568A (de)
CA (1) CA2326755A1 (de)
DE (1) DE69929183T2 (de)
ES (1) ES2253887T3 (de)
NZ (1) NZ507782A (de)
WO (1) WO1999055735A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363931A4 (de) * 2001-02-01 2004-04-07 Tanox Inc Verfahren zur herstellung und identifizierung von monoklonalen antikörpern gegen eine grosse anzahl humaner antigene
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
EP2154242B1 (de) * 2007-06-07 2016-01-06 Keiichi Fukuda Verfahren zur einleitung von differenzierung in myokardiale zellen mittels g-csf
RU2531521C2 (ru) 2007-12-05 2014-10-20 Чугаи Сейяку Кабусики Кайся Антитело против nr10 и его применение
GB0812277D0 (en) * 2008-07-04 2008-08-13 Fusion Antibodies Ltd Antibody and uses thereof
MX2013009859A (es) 2011-03-01 2014-02-28 Novo Nordisk As Ligandos dr3 antagonicos.
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
WO2016207124A1 (en) 2015-06-25 2016-12-29 F. Hoffmann-La Roche Ag Cell based assay for determining antibody or ligand binding and function
TW202128222A (zh) 2019-11-20 2021-08-01 日商中外製藥股份有限公司 含有抗體之製劑
CN114292843B (zh) * 2021-12-03 2023-07-21 中国科学院精密测量科学与技术创新研究院 一种基因兴奋剂的CRISPR/Cas12a检测体系及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
JP3417558B2 (ja) * 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド 配位子作用薬および拮抗薬の選択
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
AUPM375094A0 (en) * 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules and methods for assaying cytokine function
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
WO1997012977A1 (en) * 1995-10-05 1997-04-10 G.D. Searle & Co. Novel g-csf receptor agonists

Also Published As

Publication number Publication date
CN1326880C (zh) 2007-07-18
DE69929183D1 (de) 2006-02-02
AU764653B2 (en) 2003-08-28
EP1073683A4 (de) 2001-08-22
EP1073683A1 (de) 2001-02-07
CA2326755A1 (en) 1999-11-04
CN1298412A (zh) 2001-06-06
KR20010043112A (ko) 2001-05-25
KR100479790B1 (ko) 2005-03-30
NZ507782A (en) 2003-12-19
CN101070344A (zh) 2007-11-14
WO1999055735A1 (en) 1999-11-04
EP1073683B1 (de) 2005-12-28
JP3979008B2 (ja) 2007-09-19
AU2003252863A1 (en) 2003-11-06
AU3673299A (en) 1999-11-16
ES2253887T3 (es) 2006-06-01
JP2002512782A (ja) 2002-05-08
DE69929183T2 (de) 2006-08-24
BR9910568A (pt) 2001-09-11

Similar Documents

Publication Publication Date Title
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
BRPI0513135A (pt) bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
WO2005058815A3 (en) Ip-10 antibodies and their uses
CY1112101T1 (el) Νευροτροφικοι παραγοντες
AR055191A1 (es) Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
PH12012501006A1 (en) Compositions and methods relating to anti-igf-1 receptor antibodies
SG160224A1 (en) Novel peptides that bind to the erythropoietin receptor
DE60028970D1 (de) An her2 bindende peptidverbindungen
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
NO20011759L (no) Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi
CA2395724A1 (en) NUCLEIC ACIDS, PROTEINS AND ANTIBODIES
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
DE602005016446D1 (de) 5-HT4-Rezeptoragonistenverbindungen
ATE314396T1 (de) G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung
EP1433792A3 (de) Menschlische-rezeptor Proteine; verwandte Reagenzien und Methoden
Benjamin et al. Platelet-derived growth factor stimulates growth factor receptor binding protein-2 association with Shc in vascular smooth muscle cells.
Sfeir et al. Expression of phosphophoryn is sufficient for the induction of matrix mineralization by mammalian cells
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
AR029624A1 (es) Anticuerpos o fragmentos de anticuerpos anti-idiotipicos recombinantes y composicion farmaceutica que los contiene
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
BR0308401A (pt) Anticorpo humano anti-hfasl isolado, ou porção de ligação de antìgeno do mesmo, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para inibir as atividades de hfasl, e de fasl, e para tratar ou prevenir um distúrbio no qual a atividade de fasl é prejudicial, composição farmacêutica, e, uso de anticorpo ou de fragmento.
WO1996031603A3 (en) Methods and compositions for regulating fadd
ATE514718T1 (de) Peptabody für krebsbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties